Quince Therapeutics (QNCX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Quince Therapeutics is set to release its Q2 2025 earnings on August 12th, with analysts anticipating an earnings report of ($0.28) per share for the quarter.
• The company recently posted earnings of ($0.34) per share, falling short of analysts' expectations by $0.10.
• Several analysts have a positive outlook on Quince Therapeutics, with an average "Buy" rating and a consensus price target of $8.29 for the stock.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Trading Down 1.8%

QNCX opened at $1.66 on Thursday. The company's 50 day moving average is $1.52 and its 200-day moving average is $1.36. The company has a market cap of $89.01 million, a P/E ratio of -1.19 and a beta of 1.02. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 0.82.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on QNCX. Citigroup began coverage on Quince Therapeutics in a research note on Tuesday. They issued an "outperform" rating for the company. D. Boral Capital reiterated a "buy" rating and set a $4.00 price objective on shares of Quince Therapeutics in a research report on Thursday, July 17th. JMP Securities initiated coverage on shares of Quince Therapeutics in a research report on Tuesday. They set a "market outperform" rating and a $9.00 price target on the stock. Citizens Jmp began coverage on Quince Therapeutics in a research note on Tuesday. They issued a "strong-buy" rating and a $9.00 price objective on the stock. Finally, Wall Street Zen lowered Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $8.29.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.